Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-choline PET-CT for early response assessment during cabazitaxel in metastatic castration-resistant prostate cancer
NL-OMON46039Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Sep 2017
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Vrije University Medical Center. Primary endpoints: Accuracy of FCH-PET measures after one cycle for detecting clinical response after 3 cycles and Accuracy of FCH-PET measures after one cycle for detecting clinical response after 6 cycles. Started Sep 2017; status: active, not recruiting.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON46039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46039.